Amgen

AMGN

Market cap $148B

Overview Fund Activity

274.71 USD

+1.62

0.59%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

275.71

+1.00

0.36%

1 day

0.59%

5 days

-1.37%

1 month

-6.12%

3 months

-5.29%

6 months

-13.39%

Year to date

5.95%

1 year

-17.45%

5 years

10.73%

10 years

78.49%

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 28,000

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

12% more repeat investments, than reductions

Existing positions increased: 1,210 | Existing positions reduced: 1,081

2.79% more ownership

Funds ownership: 78.51% [Q1] → 81.3% (+2.79%) [Q2]

3% less funds holding

Funds holding: 2,891 [Q1] → 2,806 (-85) [Q2]

9% less capital invested

Capital invested by funds: $131B [Q1] → $120B (-$11.2B) [Q2]

13% less call options, than puts

Call options by funds: $1.9B | Put options by funds: $2.17B

18% less first-time investments, than exits

New positions opened: 144 | Existing positions closed: 176

46% less funds holding in top 10

Funds holding in top 10: 74 [Q1] → 40 (-34) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$261

5% downside

Avg. target

$311

13% upside

High target

$342

24% upside

6 analyst ratings

1 positive

17%

4 neutral

67%

1 negative

17%

Piper Sandler David Amsellem	$342	Overweight Maintained	25 Aug 2025
Citigroup Geoff Meacham	$310	Neutral Maintained	6 Aug 2025
Morgan Stanley Terence Flynn	$333	Equal-Weight Maintained	6 Aug 2025
UBS Trung Huynh	$317	Neutral Maintained	6 Aug 2025
B of A Securities Tim Anderson	$261	Underperform Maintained	23 Jul 2025
Cantor Fitzgerald Carter Gould	$305	Neutral Reiterated	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 29 articles about AMGN published over the past 30 days

Zacks Investment Research

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Zacks Investment Research

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Zacks Investment Research

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen: Buy The Dip Opportunity

Amgen offers a compelling value and income opportunity after a recent price dip, trading below historical valuation multiples. AMGN posted strong Q2 results with robust performance across its innovative biologics and biosimilars portfolio. AMGN is well positioned for long-term growth, supported by a strong pipeline, demographic tailwinds, and a solid balance sheet with a 3.4% dividend yield.

Amgen: Buy The Dip Opportunity

The Motley Fool

2 Healthcare Dividend Stocks to Buy and Hold

Between labor-market data and potential interest-rate cuts, Wall Street has a lot on its plate right now. In an environment like this one, it can be helpful to invest in solid, dividend-paying stocks -- and due to its non-cyclical nature, the healthcare sector is a good place to find some.

2 Healthcare Dividend Stocks to Buy and Hold

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar.

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

US FDA to step up enforcement of pharma ads, sends enforcement letters

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply with regulations that are already on the books, senior administration officials said on Tuesday.

US FDA to step up enforcement of pharma ads, sends enforcement letters

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.

Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD).

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

The Motley Fool

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today

Quick -- what were you doing back in September of 2022? Were you buying $10,000 of stock in Amgen (AMGN -1.17%)?

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today

See News Rankings

Charts implemented using Lightweight Charts™